Waltham, Mass.-based Thermo Fisher's specialty diagnostics business closes its $470 million buyout of the German in-vitro diagnostics maker and launches its first product in Europe.
The ink was hardly dried on the paperwork for Thermo Fisher Scientific Inc.'s deal to acquire German in-vitro diagnostics maker B.R.A.H.M.S. AG for roughly $470 million before the union's first product hit the market.
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
The New York Times lists the 10 most expensive hospitals in the United States, based on CMS data